Nyxoah (NASDAQ:NYXH) PT Lowered to $13.00 at Oppenheimer

Nyxoah (NASDAQ:NYXH) had its price objective trimmed by Oppenheimer from $15.00 to $13.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research firms have also weighed in on NYXH. HC Wainwright reissued a buy rating and set a $18.00 price objective on shares of Nyxoah in a research note on Wednesday. Stifel Nicolaus reduced their price target on Nyxoah from $27.00 to $19.00 and set a buy rating on the stock in a report on Monday, June 24th. Finally, Cantor Fitzgerald dropped their price objective on shares of Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a report on Wednesday, May 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nyxoah has an average rating of Buy and a consensus price target of $17.20.

Nyxoah Stock Performance

NASDAQ:NYXH opened at $8.54 on Wednesday. The company has a market cap of $212.99 million, a P/E ratio of -5.21 and a beta of 1.44. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00. The company’s 50-day moving average price is $8.34 and its 200-day moving average price is $10.62. The company has a current ratio of 3.94, a quick ratio of 3.70 and a debt-to-equity ratio of 0.13.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.45). The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.20 million. Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. On average, sell-side analysts forecast that Nyxoah will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 50,699 shares of the company’s stock, valued at approximately $684,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.